REFERENCES

REFERENCES

American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). American Psychiatric Publishing. 

Andreasen, N. C., et al. (2011). Brain structure abnormalities in schizophrenia: Evidence from neuroimaging. Archives of General Psychiatry, 68(2), 123-133. 

Cannon, T. D., Chung, Y., He, G., Sun, D., Jacobson, A., van Erp, T. G. M., … Bearden, C. E. (2021). Genetics and the predictive nature of biomarkers in schizophrenia. Nature Reviews Genetics, 22(4), 217–231. 

Fillman, S. G., & Weickert, C. S. (2020). Immune dysfunction in schizophrenia: Treatment implications. Journal of Psychiatry and Neuroscience, 45(4), 245–257. 

Global Burden of Disease. (2018). Global burden of mental disorders and cognitive aging. Lancet Psychiatry, 5(4), 327–336. 

Gur, R. E., & Gur, R. C. (2019). Gender differences in schizophrenia: New insights and research directions. Schizophrenia Research, 204, 16-23. 

Kane, J. M., Agid, O., Baldwin, M. L., Howes, O., Lindenmayer, J. P., & Marder, S. (2018). Clinical guidance on the identification and management of treatment-resistant schizophrenia. The Journal of Clinical Psychiatry, 79(1), 17ac12065. 

Keshavan, M. S., Nasrallah, H. A., & Tandon, R. (2020). Schizophrenia, "just the facts" 6. Moving ahead with the schizophrenia concept: From the elephant to the mouse. Schizophrenia Research, 218, 3-9. 

Kim, D. et al. (2019). Stem cell therapy and neurotrophic factors in schizophrenia. Nature Reviews Neuroscience, 20(1), 1-15. 

Kopelowicz, A., et al. (2010). Cognitive-behavioural therapy in schizophrenia: A review and new insights. Schizophrenia Bulletin, 36(1), 26-36. 

Leucht, S., et al. (2012). Side effects of antipsychotic medications. The Lancet, 379(9833), 2248-2259. 

McGorry, P., Nelson, B., Goldstone, S., & Yung, A. (2018). Clinical staging: A heuristic model for psychiatry and youth mental health. Medical Journal of Australia, 187(7), S40–S42. 

Meyer, J. S., & Quenzer, L. F. (2018). Psychopharmacology: Drugs, the brain, and behaviour. Oxford University Press.

Morrison, A. P., Turkington, D., Pyle, M., Spencer, H., Brabban, A., Dunn, G., ... & Hutton, P. (2014). Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: A single-blind randomized controlled trial. The Lancet, 383(9926), 1395–1403.  

Mueser, K. T., & McGurk, S. R. (2004). Schizophrenia. Lancet, 363(9426), 2063-2072. 

Murray, R. M., et al. (2017). The link between cannabis and schizophrenia. Psychological Medicine, 47(2), 97-108. 

Müller, N., et al. (2015). Inflammation and schizophrenia: Pathophysiological mechanisms. Progress in Neurobiology, 121, 25-32. 

Nasrallah, H. A., & Tandon, R. (2019). Moving schizophrenia research from biology to treatment. Schizophrenia Bulletin, 45(1), 22-28. 

National Institute of Mental Health. (2022). Schizophrenia. Retrieved from https://www.nimh.nih.gov

Phillips, K. (2024). Schizoprenia [PowerPoint slides]. Department of Neuroscience, Virginia Tech. 

Purcell, S. M., et al. (2009). Common genetic risk variants for schizophrenia. Nature, 460(7256), 748-752. 

Ripke, S., et al. (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature, 511(7510), 421-427. 

IMAGES

Figure 1- Aetiology

Schizoprenia Aetiology. (2024). Created using Microsoft Copilot with the prompt “Schizoprenia Aetiology.”

Figure 2- Clinical Presentation

Schizoprenia Clinical Presentation. (2024). Created using Microsoft Copilot with the prompt “Schizoprenia Clinical Presentation.”

Figure 3- Treatments and Outlooks

Schizoprenia Treatment and Outlooks. (2024). Created using Microsoft Copilot with the prompt “Schizoprenia Treatment and Outlooks.”

Figure 4- Epidemiology

Schizoprenia Epidemiology. (2024). Created using Microsoft Copilot with the prompt “Schizoprenia Epidemiology.”

Figure 5- Looking Ahead

Schizoprenia Looking Ahead. (2024). Created using Microsoft Copilot with the prompt “Schizoprenia Looking Ahead.”